Advantest Corp (ATE)

12.61
0.53 4.37
OTC : Technology
Prev Close 12.08
Open 12.60
Day Low/High 12.59 / 12.62
52 Wk Low/High 7.01 / 12.08
Volume 4.21K
Avg Volume 20.40K
Exchange OTC
Shares Outstanding 174.57M
Market Cap 1.71B
EPS 0.62
P/E Ratio N/A
Div & Yield 0.16 (1.70%)

Latest News

Antibe Therapeutics Inc. Announces Pricing Of Offering

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announces that it will file today an amended and restated preliminary short form prospectus (the...

IIROC Trading Resumption - ATE

Antibe Therapeutics Inc. Announces Proposed Offering Of Units

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today that it has filed a preliminary short form prospectus in connection with a proposed...

IIROC Trading Halt - ATE

Antibe Therapeutics Engages Topstone Research And Appoints Dr Francis Chan As Key Advisor For Phase 2 Clinical Trial Of ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF), a diversified biotechnology company is providing an update on the clinical development program for ATB-346, its lead drug candidate targeting...

Antibe Therapeutics Advances Development Of ATB-352 In Wake Of Growing Global Opioid Epidemic

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that is has formally commenced Investigational New Drug ("IND") enabling pre-clinical studies for its second pipeline drug,...

Antibe Therapeutics To Present At Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co.

Antibe Therapeutics Provides Update On Clinical Development Program For Its Lead Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) is pleased to provide an update on its clinical development program for ATB-346, its lead drug that targets the global need for a safer drug for...

Antibe Therapeutics Announces Grant Of Stock Options

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to...

Antibe's Founder And Chief Scientific Officer To Receive Distinguished Lifetime Achievement Award In Research

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce today that its founder and Chief Scientific Officer, Dr.

Antibe Therapeutics Reports Q3 2017 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results on Wednesday, March 1 st for the fiscal quarter ended December 31, 2016.

IIROC Trading Resumption - ATE

IIROC Trading Halt - ATE

Antibe Therapeutics Engages MKR Group For U.S. Investor Relations

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) today announced that it has retained MKR Group, Inc.

Antibe Therapeutics Announces The Launch Of PentOS OI™ Max, Its Newest Bone Graft Substitute For Oral And Maxillofacial Surgery

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) today announced that its subsidiary Citagenix Inc.

Antibe Therapeutics Announces Change Of Auditor To Ernst & Young

Antibe Therapeutics Announces Change Of Auditor To Ernst & Young

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) announced today that its board of directors (the "Board") has approved a change of the Company's auditor.

Antibe Therapeutics Raises $2.4 Million In First Tranche Of Private Placement

Antibe Therapeutics Raises $2.4 Million In First Tranche Of Private Placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce the successful completion of the first tranche of a private placement of units consisting of brokered and non-brokered...

Antibe Therapeutics Reports Q2 2017 Interim Financial And Operating Results

Antibe Therapeutics Reports Q2 2017 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE) (OTCQX:ATBPF) filed its financial and operating results on Tuesday, November 29 for the fiscal quarter ended September 30, 2016.

Antibe Therapeutics Confirms Non-Addictive Properties For Its Second Pipeline Drug, ATB-352, A Potent, Non-Addictive Pain-Killer

Antibe Therapeutics Confirms Non-Addictive Properties For Its Second Pipeline Drug, ATB-352, A Potent, Non-Addictive Pain-Killer

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain.

Antibe Therapeutics Announces Payment In Kind Election

Antibe Therapeutics Announces Payment In Kind Election

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) announces it has elected to pay in kind all interest due October 15, 2016 under the Company's 10% senior secured convertible debentures due October 15, 2018 (the...

Antibe Therapeutics Announces Launch Of Strategic Growth Initiative In The U.S. Market For Dental Biologics

Antibe Therapeutics Announces Launch Of Strategic Growth Initiative In The U.S. Market For Dental Biologics

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announces that its subsidiary Citagenix Inc.

Antibe Therapeutics To Present At 2016 Rodman & Renshaw Global Investment Conference

Antibe Therapeutics To Present At 2016 Rodman & Renshaw Global Investment Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announced that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment...

Antibe Therapeutics Announces The Launch Of Neomem® FlexPlus, A High-Performance Barrier Membrane For Oral Surgery

Antibe Therapeutics Announces The Launch Of Neomem® FlexPlus, A High-Performance Barrier Membrane For Oral Surgery

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) today announces that its subsidiary Citagenix Inc.

Antibe Therapeutics Announces Successful Phase 2 Trial Of ATB-346 In Osteoarthritis

Antibe Therapeutics Announces Successful Phase 2 Trial Of ATB-346 In Osteoarthritis

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE; OTCQX: ATBPF) is pleased to announce the successful completion of its phase 2 clinical trial of ATB-346 in osteoarthritis ("OA").

Antibe Therapeutics Reports 2016 Year-End Financial And Operating Results

Antibe Therapeutics Reports 2016 Year-End Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Friday, July 29 for the fourth quarter and the year ended March 31, 2016.

Antibe Therapeutics Announces The Appointment Of New Board Member And Provides Update On Phase 2 Trial Of ATB-346

Antibe Therapeutics Announces The Appointment Of New Board Member And Provides Update On Phase 2 Trial Of ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE, OTCQX:ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce the appointment of Yung Wu to its Board of Directors.

Antibe Therapeutics Presenting Update On ATB-346 At International Hydrogen Sulfide Conference

Antibe Therapeutics Presenting Update On ATB-346 At International Hydrogen Sulfide Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4 th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3 rd to 5th.

Advantest Earns 28th Consecutive Ranking As A 10 BEST Supplier Of Semiconductor Test Equipment, Excelling As Global Customers Rate System Uptime As Paramount In The Industry

Advantest Earns 28th Consecutive Ranking As A 10 BEST Supplier Of Semiconductor Test Equipment, Excelling As Global Customers Rate System Uptime As Paramount In The Industry

For the 28 th consecutive year, leading semiconductor test equipment supplier, Advantest Corporation (TSE:6857), has been named a distinguished 10 BEST Supplier of Chip Making Equipment in the annual VLSIresearch Customer...